« Reprise Biotech's Losing RNAi Interest? | Main | Analysis of 2010 Biotech M&A's »

03/27/2011

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0147e37ffb32970b

Listed below are links to weblogs that reference BMS CEO Seemingly Gloats Over Impilimumab:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

I have to wonder about the sustainability of such pricing attempts in this new dawn of much much more managed reimbursement and government pricing. I know that theory is that the drug saves a lot compared to other treatment costs but $120 K for 4 months survival increase? One must wonder. It has to hurt adoption rates doesn't it?

Account Deleted

It will be interesting to see how well this drug does with a $120K price tag, which came out around the same month it was announced that the CEO got a 40% pay rise... not sure whether to be cynical or sigh at the timing.

Totally agree that this is a long term game and the previous BMS crowing over Sprycel and Onglyza pre-launch has not been met with much subsequent commercial success. Sometimes it's best to count the chickens first!

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada